

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07C 311/29, C07D 309/14, 211/66, A61K 31/19, 31/215, 31/35, 31/445</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/07675</p> <p>(43) International Publication Date: 18 February 1999 (18.02.99)</p>		
<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <p>(21) International Application Number: PCT/IB98/01113</p> <p>(22) International Filing Date: 21 July 1998 (21.07.98)</p> <p>(30) Priority Data: 60/055,207 8 August 1997 (08.08.97) US</p> <p>(71) Applicant (for all designated States except US): PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): ROBINSON, Ralph, Pelton [US/US]; 30 Friar Tuck Drive, Gales Ferry, CT 06335 (US).</p> <p>(74) Agents: SPIEGEL, A., J. et al.; c/o Green, Mark, Charles, Urquhart-Dykes & Lord, 91 Wimpole Street, London W1M 8AH (GB).</p> </td> <td style="width: 50%; vertical-align: top;"> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p> </td> </tr> </table>			<p>(21) International Application Number: PCT/IB98/01113</p> <p>(22) International Filing Date: 21 July 1998 (21.07.98)</p> <p>(30) Priority Data: 60/055,207 8 August 1997 (08.08.97) US</p> <p>(71) Applicant (for all designated States except US): PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): ROBINSON, Ralph, Pelton [US/US]; 30 Friar Tuck Drive, Gales Ferry, CT 06335 (US).</p> <p>(74) Agents: SPIEGEL, A., J. et al.; c/o Green, Mark, Charles, Urquhart-Dykes & Lord, 91 Wimpole Street, London W1M 8AH (GB).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>
<p>(21) International Application Number: PCT/IB98/01113</p> <p>(22) International Filing Date: 21 July 1998 (21.07.98)</p> <p>(30) Priority Data: 60/055,207 8 August 1997 (08.08.97) US</p> <p>(71) Applicant (for all designated States except US): PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): ROBINSON, Ralph, Pelton [US/US]; 30 Friar Tuck Drive, Gales Ferry, CT 06335 (US).</p> <p>(74) Agents: SPIEGEL, A., J. et al.; c/o Green, Mark, Charles, Urquhart-Dykes & Lord, 91 Wimpole Street, London W1M 8AH (GB).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>			
<p>(54) Title: ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES</p> <p>(57) Abstract</p> <p>A compound of formula (I) or the pharmaceutically acceptable salts thereof, wherein R¹ is (C₁-C₆)alkyl; R² is (C₁-C₆)alkyl; or R¹ and R² taken together with the carbon atom to which they are attached form a ring selected from (C₅-C₇)cycloalkyl, 4-tetrahydropyranyl and 4-piperidinyl; R³ is hydrogen or (C₁-C₆)alkyl; and Y is a substituent of any of the carbon atoms of the phenyl ring capable of supporting an additional bond, preferably from 1 to 2 substituents (more preferably one substituent, most preferably one substituent in the 4-position) on the phenyl ring, independently selected from hydrogen, fluoro, chloro, trifluoromethyl, (C₁-C₆)alkoxy, trifluoromethoxy, difluoromethoxy and (C₁-C₆)alkyl.</p>				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5 ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES Background of the Invention

 The present invention relates to aryloxyarylsulfonylamino hydroxamic acid derivatives. These compounds are selective inhibitors of matrix metalloproteinase-13 and as such are useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, bone resorption, loosening of artificial joint implants, atherosclerosis, multiple sclerosis, ocular angiogenesis (for example macular degeneration) and other diseases characterized by matrix metalloproteinase activity.

10 This invention also relates to a method of using such compounds in the treatment of the above diseases in mammals, especially humans, and to the pharmaceutical compositions useful therefor.


 There are a number of enzymes which effect the breakdown of structural proteins and which are structurally related metalloproteases. Matrix-degrading metalloproteinases, such as gelatinase, stromelysin and collagenase, are involved in tissue matrix degradation (e.g. collagen collapse) and have been implicated in many pathological conditions involving abnormal connective tissue and basement membrane matrix metabolism, such as arthritis (e.g. osteoarthritis and rheumatoid arthritis), tissue ulceration (e.g. corneal, epidermal and gastric ulceration), abnormal wound healing, periodontal disease, bone disease (e.g. Paget's disease and osteoporosis), tumor metastasis or invasion, as well as HIV-infection (J. Leuk. Biol., 52 (2): 244-248, 1992).

20 Tumor necrosis factor is recognized to be involved in many infectious and auto-immune diseases (W. Friers, FEBS Letters, 1991, 285, 199). Furthermore, it has been shown that TNF is the prime mediator of the inflammatory response seen in sepsis and septic shock (C.E. Spooner et al., Clinical Immunology and Immunopathology, 1992, 62 S11).

30 Summary of the Invention

 The present invention relates to a compound of the formula

-2-



5

or the pharmaceutically acceptable salts thereof, wherein

R^1 is (C_1-C_6) alkyl;

R^2 is (C_1-C_6) alkyl;

or R^1 and R^2 taken together with the carbon atom to which they are attached form a ring

10 selected from (C_5-C_7) cycloalkyl, 4-tetrahydropyranyl and 4-piperidiny;

R^3 is hydrogen or (C_1-C_6) alkyl; and

Y is a substituent on any of the carbon atoms of the phenyl ring capable of supporting an additional bond, preferably from 1 to 2 substituents (more preferably one substituent, most preferably one substituent in the 4-position) on the phenyl ring, independently selected from
 15 hydrogen, fluoro, chloro, trifluoromethyl, (C_1-C_6) alkoxy, trifluoromethoxy, difluoromethoxy and (C_1-C_6) alkyl.

The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof.

20 The term "alkoxy", as used herein, includes O-alkyl groups wherein "alkyl" is defined above.

The present invention also relates to the pharmaceutically acceptable acid addition salts of compounds of the formula I. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are those
 25 which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)]salts.

30


The invention also relates to base addition salts of formula I. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those

-3-

5 compounds of formula I that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium); ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower
 10 alkanolammonium and other base salts of pharmaceutically acceptable organic amines.

The compound of formula I may have chiral centers and therefore exist in different enantiomeric forms. This invention relates to all optical isomers and stereoisomers of the compounds of formula I and mixtures thereof.

This invention also encompasses pharmaceutical compositions containing and methods
 15 of treating or preventing comprising administering prodrugs of compounds of the formula I. Compounds of formula I having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs. Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues which are covalently joined through peptide bonds to free amino, hydroxy or carboxylic acid groups of
 20 compounds of formula I. The amino acid residues include the 20 naturally occurring amino acids commonly designated by three letter symbols and also include, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone. Prodrugs also include compounds wherein carbonates, carbamates, amides and alkyl esters which are covalently
 25 bonded to the above substituents of formula I through the carbonyl carbon prodrug sidechain. Prodrugs also include compounds of formula I in which the hydroxamic acid and carbonyl moiety when taken together form a group of the formula



30

wherein R^1 , R^2 and Y are as defined in formula I and U and V are independently carbonyl, methylene, SO_2 or SO_3 , and b is an integer from one to three wherein each methylene group is optionally substituted with hydroxy.

5 Preferred compounds of formula I include those wherein Y is hydrogen, fluoro or chloro, preferably 4-fluoro or 4-chloro.

Other preferred compounds of formula I include those wherein R¹ and R² taken together with the carbon atom to which they are attached form a cyclopentyl or 4-tetrahydropyranyl ring.

Other preferred compounds of formula I include those wherein R¹ and R² are both
10 methyl.

Other preferred compounds of formula I include those wherein R³ is hydrogen.

Specific preferred compounds of formula I include the following:

3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1-hydroxy-carbamoylcyclopentyl)amino]-
propionic acid ethyl ester,
15 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1-hydroxy-carbamoylcyclopentyl)
amino]propionic acid,

3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1-hydroxycarbamoyl-1-
methylethyl)amino]propionic acid ethyl ester, and

3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1-hydroxy-carbamoyl-1-
20 methylethyl)amino]propionic acid.

Other compounds of formula I include the following:

3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(4-hydroxycarbamoyltetrahydropyran-4-yl)-
amino]propionic acid,

3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(4-hydroxycarbamoyltetrahydropyran-4-yl)-
25 amino]propionic acid ethyl ester,

3-[[4-(4-chlorophenoxy)benzenesulfonyl]-(4-hydroxycarbamoyltetrahydropyran-4-yl)-
amino]propionic acid,

3-[[4-(4-chlorophenoxy)benzenesulfonyl]-(4-hydroxycarbamoyltetrahydropyran-4-yl)-
amino]propionic acid ethyl ester,

3-[(4-hydroxycarbamoyltetrahydropyran-4-yl)-(4-phenoxybenzenesulfonyl)amino]-
30 propionic acid,

3-[(4-hydroxycarbamoyltetrahydropyran-4-yl)-(4-phenoxybenzenesulfonyl)amino]-
propionic acid ethyl ester,

3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(4-hydroxycarbamoylpiperidin-4-yl)-
35 amino]propionic acid ethyl ester,

3-[[4-(4-chlorophenoxy)benzenesulfonyl]-(1-hydroxycarbamoyl-1-methylethyl)amino]-
propionic acid,

3-[[4-(4-chlorophenoxy)benzenesulfonyl]-(1-hydroxycarbamoyl-1-methylethyl)amino]-
propionic acid ethyl ester.

5 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1-hydroxycarbamoylcyclohexyl)amino]-
propionic acid.

3-[(1-hydroxycarbamoylcyclopentyl)-(4-phenoxybenzenesulfonyl)amino]propionic acid, and

3-[[4-(4-chlorophenoxy)benzenesulfonyl]-(1-hydroxycarbamoylcyclopentyl)amino]-
10 propionic acid.

The present invention also relates to a pharmaceutical composition for (a) the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, bone resorption, loosening of artificial joint implants, atherosclerosis, multiple sclerosis, ocular angiogenesis (for example macular degeneration) and other diseases characterized by matrix metalloproteinase activity, or (b) the selective inhibition of matrix metalloproteinase-13 in a mammal, including a human, comprising an amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, effective in such treatments and a pharmaceutically acceptable carrier.

The present invention also relates to a method for the selective inhibition of matrix metalloproteinase-13 or in a mammal, including a human, comprising administering to said 20 mammal an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.


The present invention also relates to a method for treating a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, bone resorption, loosening of artificial joint implants, atherosclerosis, multiple sclerosis, ocular angiogenesis (for example macular degeneration) and other diseases characterized by matrix metalloproteinase-13 activity in a mammal, including a human, comprising administering to said mammal an amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, effective in treating such a condition.

30 Detailed Description of the Invention

The following reaction Schemes illustrate the preparation of the compounds of the present invention. Unless otherwise indicated Y, R¹, R² and R³ in the reaction Schemes and the discussion that follow are defined as above.


5

Scheme 1




5

Scheme 1 Cont'd



- 5 Scheme 1 refers to the preparation of compounds of the formula I from compounds of the formula VII. Referring to Scheme 1, the amino acid compound of formula VII, wherein R¹⁶ is benzyl, is converted to the corresponding compound of formula VI by reaction with a reactive functional derivative of an arylsulfonic acid compound of the formula



VIII

- 10 in the presence of a base, such as triethylamine, and a polar solvent, such as tetrahydrofuran, 1,2-dimethoxyethane, dioxane, water or acetonitrile, preferably 1,2-dimethoxyethane. The reaction mixture is stirred, at room temperature, for a time period between about 10 minutes to about 24 hours, preferably about 60 minutes.

- The arylsulfonylamino compound of formula VI, wherein R¹⁶ is benzyl, is converted to
 15 the corresponding compound of formula V, wherein R¹⁶ is the group 3-tert-butyl-dimethylsilanyloxypropyl by reaction with tert-butyl-(3-halo-propoxy)dimethylsilane, preferably the iodide derivative, in the presence of a base, such as potassium carbonate, cesium carbonate, potassium hexamethyldisilazide, or sodium hydride, preferably potassium hexamethyldisilazide. The reaction is stirred in a polar solvent, such as dimethylformamide or N-
 20 methylpyrrolidin-2-one, at room temperature, for a time period between about 2 hours to about 48 hours, preferably about 18 hours.

- The compound of formula V is converted to a carboxylic acid derivative of formula IV by reaction with boron trifluoride-etherate complex to form an intermediate alcohol, followed by oxidation and protection by esterification. Specifically, the reaction with boron trifluoride-etherate
 25 complex is performed in an inert solvent such as methylene chloride, chloroform, preferably methylene chloride, at room temperature for about 15 minutes to about 4 hours, preferably about one hour. Oxidation of the alcohol is facilitated by using chromium trioxide in aqueous sulfuric acid (Jones Reagent) at about 0°C for about one to about 6 hours, preferably about 2 hours. Protection of the carboxylic acid is facilitated by treatment of the free acid with an alkylating
 30 agent such as R³-L, wherein L is a leaving group such as iodo, bromo, mesylate, or tosylate, preferably iodo, with a base, such potassium carbonate or cesium carbonate, preferably potassium carbonate, in a polar solvent such as dimethylformamide, N-methylpyrrolidin-2-one or tetrahydrofuran, preferably dimethyl formamide, for about 1 to about 24 hours, preferably 16 hours, at about room temperature.

5 The compound of formula IV is converted to a compound of formula III by removal of the R¹⁶ protecting group by hydrogenolysis using palladium on carbon in a solvent such as methanol or ethanol, for a period from about 30 minutes to about 48 hours, preferably 16 hours, at a temperature of about 20°C to about 25°C, i.e. room temperature.

10 The carboxylic acid compound of formula III is converted to the hydroxamic acid derivative of formula II, wherein R¹⁶ is benzyl, by activation of the compound of formula III followed by reaction with benzylhydroxylamine. The compound of formula III is activated by treatment with (benzotriazol-1-yloxy)tris(dimethylamino) phosphonium hexafluorophosphate in the presence of a base, at room temperature, in a polar solvent. The aforesaid reaction is conducted for a period of about 15 minutes to about 4 hours, preferably about 1 hour. The
15 activated compound derived from formula III is converted *in situ* to the compound of formula II by reaction with benzylhydroxylamine hydrochloride. The reaction with benzylhydroxylamine hydrochloride is conducted for about 1 hour to about 5 days, preferably for about 16 hours, at a temperature of about 40°C to about 80°C, preferably about 60°C. Suitable bases include N-methylmorpholine or diisopropylethylamine, preferably diisopropylethylamine. Suitable solvents
20 include N,N-dimethylformamide or N-methylpyrrolidin-2-one, preferably N,N-dimethylformamide.

 The compound of formula II is converted into a compound I by removal of the hydroxylamine protecting group. Removal of the hydroxylamine protecting group is carried out by hydrogenolysis of the benzyl protecting group using catalytic palladium on barium sulfate in a polar solvent at a temperature from about 20°C to about 25°C, i.e. room temperature, for a
25 period of about 1 hour to about 5 hours, preferably about 3 hours.

 Compounds of formula VII and VIII are commercially available or can be made by methods well known to those of ordinary skill in the art.

 Pharmaceutically acceptable salts of the acidic compounds of the invention are salts formed with bases, namely cationic salts such as alkali and alkaline earth metal salts, such as
30 sodium, lithium, potassium, calcium, magnesium, as well as ammonium salts, such as ammonium, trimethyl-ammonium, diethylammonium, and tris-(hydroxymethyl)-methylammonium salts.

 Similarly acid addition salts, such as of mineral acids, organic carboxylic and organic sulfonic acids e.g. hydrochloric acid, methanesulfonic acid, maleic acid, are also possible
35 provided a basic group, such as pyridyl, constitutes part of the structure.

 The compounds of the formula I which are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a
40 pharmaceutically unacceptable salt and then simply convert the latter back to the free base

5 compound by treatment with an alkaline reagent, and subsequently convert the free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol. Upon careful
10 evaporation of the solvent, the desired solid salt is obtained.

The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate,
15 lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts.

Those compounds of the formula I which are also acidic in nature, e.g., where R^3 is hydrogen, are capable of forming base salts with various pharmacologically acceptable
20 cations. Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the herein described acidic compounds of formula I. These non-toxic base salts include those
25 derived from such pharmacologically acceptable cations as sodium, potassium, calcium and magnesium, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the
30 acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum product yields.

The ability of the compounds of formula I or their pharmaceutically acceptable salts
35 (hereinafter also referred to as the MMP-13 selective compounds of the present invention) to inhibit matrix metalloproteinase-13 (collagenase 3) and, consequently, demonstrate their effectiveness for treating diseases characterized by matrix metalloproteinase-13 is shown by the following in vitro assay tests.

5

Biological AssayInhibition of Human Collagenase (MMP-1)

Human recombinant collagenase is activated with trypsin using the following ratio: 10 mg trypsin per 100 mg of collagenase. The trypsin and collagenase are incubated at room temperature for 10 minutes then a five fold excess (50 mg/10 mg trypsin) of soybean trypsin inhibitor is added.

10 mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted using the following Scheme:

10 mM \longrightarrow 120 μ M \longrightarrow 12 μ M \longrightarrow 1.2 μ M \longrightarrow 0.12 μ M

Twenty-five microliters of each concentration is then added in triplicate to appropriate wells of a 96 well microfluor plate. The final concentration of inhibitor will be a 1:4 dilution after addition of enzyme and substrate. Positive controls (enzyme, no inhibitor) are set up in wells D1-D6 and blanks (no enzyme, no inhibitors) are set in wells D7-D12.

Collagenase is diluted to 400 ng/ml and 25 μ l is then added to appropriate wells of the microfluor plate. Final concentration of collagenase in the assay is 100 ng/ml.

20 Substrate (DNP-Pro-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH₂) is made as a 5 mM stock in dimethyl sulfoxide and then diluted to 20 mM in assay buffer. The assay is initiated by the addition of 50 μ l substrate per well of the microfluor plate to give a final concentration of 10 mM.

25 Fluorescence readings (360 nm excitation, 460 nm emission) were taken at time 0 and then at 20 minute intervals. The assay is conducted at room temperature with a typical assay time of 3 hours.

Fluorescence vs time is then plotted for both the blank and collagenase containing samples (data from triplicate determinations is averaged). A time point that provides a good signal (the blank) and that is on a linear part of the curve (usually around 120 minutes) is chosen to determine IC₅₀ values. The zero time is used as a blank for each compound at each concentration and these values are subtracted from the 120 minute data. Data is plotted as inhibitor concentration vs % control (inhibitor fluorescence divided by fluorescence of collagenase alone x 100). IC₅₀'s are determined from the concentration of inhibitor that gives a signal that is 50% of the control.

35 If IC₅₀'s are reported to be <0.03 mM then the inhibitors are assayed at concentrations of 0.3 mM, 0.03 mM, 0.01 mM and 0.003 mM.

Inhibition of MMP-13

Human recombinant MMP-13 is activated with 2mM APMA (p-aminophenyl mercuric acetate) for 1.5 hours, at 37°C and is diluted to 400 ng/ml in assay buffer (50 mM Tris, pH 7.5, 200 mM sodium chloride, 5mM calcium chloride, 20mM zinc chloride, 0.02% brij). Twenty-five

5 microliters of diluted enzyme is added per well of a 96 well microfluor plate. The enzyme is then diluted in a 1:4 ratio in the assay by the addition of inhibitor and substrate to give a final concentration in the assay of 100 mg/ml.

10 mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted in assay buffer as per the inhibitor dilution scheme for inhibition of human collagenase (MMP-1):

10 Twenty-five microliters of each concentration is added in triplicate to the microfluor plate. The final concentrations in the assay are 30 mM, 3mM, 0.3 mM, and 0.03 mM.

Substrate (Dnp-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH₂) is prepared as for inhibition of human collagenase (MMP-1) and 50 ml is added to each well to give a final assay concentration of 10 mM. Fluorescence readings (360 nM excitation; 450 emission) are taken at
15 time 0 and every 5 minutes for 1 hour.


Positive controls consist of enzyme and substrate with no inhibitor and blanks consist of substrate only.

IC₅₀'s are determined as per inhibition of human collagenase (MMP-1). If IC₅₀'s are reported to be less than 0.03 mM, inhibitors are then assayed at final concentrations of 0.3 mM,
20 0.03 mM, 0.003 mM and 0.0003 mM.

The compounds of the present invention possess surprisingly selective activity against matrix metalloproteinase-13 (collagenase 3), as compared to matrix metalloproteinase-1 (collagenase 1). Specifically, the compounds of the formula I are 100 times more selective for matrix metalloproteinase-13 (collagenase 3) than matrix metalloproteinase-1 (collagenase 1)
25 and have IC₅₀'s of less than 10nM against matrix metalloproteinase-13 (collagenase 3). Table 1 lists several compounds that demonstrate the unexpected selectivity of the compounds of the invention.

5

TABLE 1



Ex.	R ¹	R ²	R ³	R	MMP-1 IC ₅₀ (nM)	MMP-13 IC ₅₀ (nM)
1	cyclopentyl	-	ethyl	4-fluorophenoxy	100	0.9
1	cyclopentyl	-	ethyl	4-fluorophenoxy	100	0.9
2	cyclopentyl	-	hydrogen	4-fluorophenoxy	360	1.2
2	cyclopentyl	-	hydrogen	4-fluorophenoxy	200	0.6
3	methyl	methyl	ethyl	4-fluorophenoxy	1200	1.6
3	methyl	methyl	ethyl	4-fluorophenoxy	1800	2.3
4	methyl	methyl	hydrogen	4-fluorophenoxy	3500	5.7
4	methyl	methyl	hydrogen	4-fluorophenoxy	2000	2.3
4	methyl	methyl	hydrogen	4-fluorophenoxy	4800	8
	cyclopentyl	-	hydrogen	methoxy	800	21
	cyclopentyl	-	hydrogen	methoxy	700	25
	methyl	methyl	hydrogen	methoxy	12000	590
	methyl	methyl	hydrogen	methoxy	12000	730
	cyclohexyl	hydrogen	hydrogen	methoxy	18	4
	cyclohexyl	hydrogen	hydrogen	methoxy	22	2

For administration to humans for the inhibition of matrix metalloproteinase-13 or the production of tumor necrosis factor (TNF), a variety of conventional routes may be used including orally, parenterally and topically. In general, the active compound will be administered orally or parenterally at dosages between about 0.1 and 25 mg/kg body weight of the subject to be treated per day, preferably from about 0.3 to 5 mg/kg. However, some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person

5 responsible for administration will, in any event, determine the appropriate dose for the individual subject.

The compounds of the present invention can be administered in a wide variety of different dosage forms, in general, the therapeutically effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.

For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.

For parenteral administration (intramuscular, intraperitoneal, subcutaneous and intravenous use) a sterile injectable solution of the active ingredient is usually prepared. Solutions of a therapeutic compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably adjusted and buffered, preferably at a pH of greater than 8, if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.

The following Examples illustrate the preparation of the compounds of the present invention. Melting points are uncorrected. NMR data are reported in parts per million (δ) and are referenced to the deuterium lock signal from the sample solvent (deuteriodimethylsulfoxide unless otherwise specified). Commercial reagents were utilized without further purification. THF refers to tetrahydrofuran. DMF refers to N,N-dimethylformamide. Chromatography refers to column chromatography performed using 32-63 mm silica gel and executed under nitrogen pressure (flash chromatography) conditions. Room or ambient temperature refers to 20 to 25°C. All non-aqueous reactions were run under

- 5 a nitrogen atmosphere for convenience and to maximize yields. Concentration at reduced pressure means that a rotary evaporator was used.

Example 1

10 3-[[4-(4-FLUOROPHENOXY)BENZENESULFONYL]-(1-HYDROXY-CARBAMOYL CYCLOPENTYL)AMINO]-PROPIONIC ACID ETHYL ESTER

(A) To a solution of 1-aminocyclopentanecarboxylic acid benzyl ester p-toluenesulfonic acid salt (200 grams, 0.51 mole) and triethylamine (177 mL, 1.27 mole) in water (1 L) and 1,2-dimethoxyethane (1 L) was added 4-(4-fluorophenoxy)benzenesulfonyl-chloride (161 grams, 0.56 moles). The mixture was stirred at room temperature for 16 hours
15 and then most of the solvent was removed by evaporation under vacuum. The mixture was diluted with ethyl acetate and was washed successively with dilute hydrochloric acid solution, water, and brine. The solution was dried over magnesium sulfate and concentrated to leave a brown solid. Trituration with diethyl ether to afforded 1-[4-(4-fluorophenoxy)benzenesulfonylamino]-cyclopentanecarboxylic acid benzyl ester as a tan
20 solid, 167 grams (70%).

(B) To a solution of 1-[4-(4-fluorophenoxy)benzenesulfonylamino]-cyclopentanecarboxylic acid benzyl ester (199 grams, 0.42 mole) in dry N,N-dimethylformamide (2.5 L) at room temperature was added potassium hexamethyldisilazide (100 grams, 0.50 mole) and, after 3 hours, tert-butyl-(3-iodopropoxy)dimethylsilane (150
25 grams, 0.50 mole). The resulting mixture was stirred at room temperature for 16 hours. Additional tert-butyl-(3-iodopropoxy)-dimethylsilane (20 grams, 0.067 mole) was then added. Stirring at room temperature was continued for a further 3.5 hours. The mixture was quenched by addition of saturated ammonium chloride solution. The N,N-dimethylformamide was removed by evaporation under vacuum. The residue was taken up in diethyl ether and
30 washed with water and brine. After drying over magnesium sulfate, the diethyl ether was evaporated to afford crude 1-[[3-(tert-butyl-dimethylsilyloxy)-propyl]-[4-(4-fluorophenoxy)benzenesulfonyl]-amino]cyclopentanecarboxylic acid benzyl ester as an amber oil (279.6 grams).

(C) To a solution of the crude 1-[[3-(tert-butyl-dimethylsilyloxy)-propyl]-[4-(4-fluorophenoxy)benzenesulfonyl]-amino]cyclopentanecarboxylic acid benzyl ester (279 grams)
35 in methylene chloride (1 L) at room temperature was added boron trifluoride etherate (103 mL, 0.84 mole). After 1 hour, the reaction was quenched by sequential addition of saturated ammonium chloride solution and water. The organic phase was separated, washed with water and brine and dried over magnesium sulfate. Evaporation of the solvent under vacuum

5 provided crude 1-[[4-(4-fluorophenoxy)benzenesulfonyl]-(3-hydroxypropyl)amino]cyclopentanecarboxylic acid benzyl ester as an amber oil (235 grams).

(D) A solution of the crude 1-[[4-(4-fluorophenoxy)benzenesulfonyl]-(3-hydroxypropyl)amino]cyclopentanecarboxylic acid benzyl ester (235 grams) in acetone (2 L) was cooled in an ice bath and treated with Jones reagent (about 200 mL) until an orange color
10 persisted. The mixture was stirred from 0°C to room temperature over 1 hour. After quenching excess oxidant with isopropanol (10 mL), the mixture was filtered and the filtrate was concentrated under vacuum. The residue was taken up in ethyl acetate, washed with water and brine, dried over magnesium sulfate and concentrated to afford a solid which was triturated with a mixture of diethyl ether and hexane to provide 1-[(2-carboxyethyl)-[4-(4-
15 fluorophenoxy)benzenesulfonyl]amino]cyclopentane carboxylic acid benzyl ester as a white solid (147 grams).

(E) To a solution of 1-[(2-carboxyethyl)-[4-(4-fluorophenoxy)benzenesulfonyl] amino]-cyclopentanecarboxylic acid benzyl ester (147 grams) in N,N-dimethyl formamide (3 L) at room temperature was added potassium carbonate (150 grams, 1.08 mole) and ethyl iodide
20 (32.4 mL, 0.405 mole). The mixture was stirred for 16 hours at room temperature. After filtration, most of the solvent was removed under vacuum. The residue was taken up in water and acidified using 6N aqueous hydrogen chloride solution. The resulting mixture was extracted with diethyl ether. The organic extract was washed with water and brine, dried over magnesium sulfate, and concentrated to yield 1-[(2-ethoxycarbonyl)ethyl]-[4-(4-
25 fluorophenoxy)benzenesulfonyl] amino]cyclopentane carboxylic acid benzyl ester as a yellow semi-solid (149.1 grams, 96%).

(F) A solution of 1-[(2-ethoxycarbonyl)ethyl]-[4-(4-fluorophenoxy)benzene sulfonyl]-amino]cyclopentanecarboxylic acid benzyl ester (74.5 grams, 0.13 mole) in ethanol (1.8 L) was treated with 10% palladium on activated carbon (7.4 grams) and hydrogenated in a
30 ParrTM shaker at 3 atmospheres pressure for 16 hours. After filtration through nylon (pore size 0.45 µm) to remove the catalyst, the solvent was evaporated to afford 1-[(2-ethoxycarbonyl)ethyl]-[4-(4-fluorophenoxy)benzenesulfonyl]amino] cyclopentanecarboxylic acid as a white foam. The reaction was repeated on the same scale to provide, in total, 125.2 grams of the desired product.

(G) Diisopropylethylamine (50 mL, 0.286 mole) and (benzotriazol-1-yloxy)tris-(dimethylamino)phosphonium hexafluorophosphate (126.5 grams, 0.286 mole) were added sequentially to a solution of 1-[(2-ethoxycarbonyl)ethyl]-[4-(4-fluorophenoxy)benzene-sulfonyl]amino]cyclopentanecarboxylic acid (125.2 grams, 0.26 mole) in N,N-dimethylformamide (2 L). The mixture was stirred for 1 hour. Additional
40 diisopropylethylamine (91 mL, 0.52 mole) and O-benzylhydroxylamine hydrochloride (53.8

5 grams, 0.338 mole) were then added and the resulting mixture was stirred at 60°C for 96 hours. After concentration under vacuum, the residue was taken up in water and acidified with 1N aqueous hydrogen chloride solution. The mixture was extracted with ethyl acetate and the extract was washed sequentially with water, saturated aqueous sodium bicarbonate solution and brine. The solution was dried over magnesium sulfate and concentrated to give
10 crude 3-((1-benzoyloxycarbamoylcyclopentyl)-[4-(4-fluorophenoxy)benzenesulfonyl]-amino)propionic acid ethyl ester as a yellow oil (164 grams).

F) A solution of crude 3-((1-benzoyloxycarbamoylcyclopentyl)-[4-(4-fluorophenoxy)-benzenesulfonyl]amino)propionic acid ethyl ester (164 grams) in ethanol (2.4 L) was treated with 5% palladium on barium sulfate (50 grams) and hydrogenated in a ParrTM shaker at 3
15 atmospheres pressure for 3 hours. After filtration through nylon (pore size 0.45 µm) to remove the catalyst, the solvent was evaporated to afford an oil. After addition of ethyl acetate and hexane, 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1-hydroxy-carbamoylcyclopentyl)amino]-propionic acid ethyl ester, a white crystalline solid (73.5 grams) was collected by filtration. The filtrate was concentrated and the residue was
20 chromatographed on silica gel eluting with 40% ethyl acetate hexane to provide more of the desired product (32.5 grams).

Mp: 79-83°C. ¹H NMR (DMSO-d₆): δ 10.40 (br s, 1 H), 8.78 (br s, 1 H), 7.80-7.77 (m, 2 H), 7.31-7.03 (m, 6 H), 4.02 (q, J = 7.3 Hz, 2 H), 3.49-3.45 (m, 2 H), 2.70-2.67 (m, 2 H), 2.24-2.21 (m, 2 H), 1.86-1.83 (m, 2 H), 1.53-1.50 (m, 4 H), 1.16 (t, J = 7.3 Hz, 3 H). MS 493
25 (M-1). Analysis calculated for C₂₃H₂₇FN₂O₇S.H₂O: C, 53.90; H, 5.70; N, 5.47. Found: C, 54.52; H, 5.63; N, 5.27.

5

Example 2**3-[[4-(4-FLUOROPHENOXY)BENZENESULFONYL]-(1-HYDROXY-CARBAMOYL-CYCLOPENTYL) AMINO]PROPIONIC ACID**

A solution of 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1-hydroxycarbamoyl cyclopentyl)-amino]propionic acid ethyl ester (106 grams, 0.214 mole) in ethanol (2.5 L) was treated with aqueous 1 N sodium hydroxide solution (856 mL, 0.856 mole) and stirred at room temperature for 2 hours. The mixture was concentrated to remove ethanol, diluted with water, acidified with 6 N aqueous hydrochloric acid solution and extracted with ethyl acetate. After washing with water and brine, the organic extract was dried over magnesium sulfate and concentrated to a foam. Crystallization from 30% ethyl acetate in hexane gave 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1-hydroxy carbamoylcyclopentyl)-amino]propionic acid as a white crystalline solid (81.5 grams, 81%).

Mp: 170-172°C. ¹H NMR (DMSO-d₆): δ 12.25 (br s, 1 H), 10.40 (br s, 1 H), 8.74 (br s, 1 H), 7.79-7.77 (m, 2 H), 7.29-7.03 (m, 6 H), 3.45-3.41 (m, 2 H), 2.61-2.57 (m, 2 H), 2.24-2.21 (m, 2 H), 1.88-1.82 (m, 2 H), 1.53-1.50 (m, 4 H). MS 465 (M-1). Analysis calculated for C₂₁H₂₃FN₂O₇S: C, 54.07; H, 4.97; N, 6.00. Found: C, 54.17; H, 5.02; N, 6.05.

20

Example 3**3-[[4-(4-FLUOROPHENOXY)BENZENESULFONYL]-(1-HYDROXYCARBAMOYL-1-METHYLETHYL)AMINO]PROPIONIC ACID ETHYL ESTER**

The title compound was prepared according to a procedure analogous to that outlined in Example 1 starting with 2-amino-2-methyl-propionic acid benzyl ester p-toluenesulfonic acid salt.

Mp: 124.8-125°C. ¹H NMR (DMSO-d₆) δ 10.37 (s, 1 H), 8.74 (s, 1 H), 7.86 (d, 2 H, J = 8.9 Hz), 7.16-7.30 (m, 4 H), 7.04 (d, 2 H, J = 8.7 Hz), 3.99 (q, 2 H, J = 7.1 Hz), 3.33-3.37 (m, 2 H), 2.62-2.66 (m, 2 H), 1.40 (s, 6 H), 1.13 (t, 3 H, J = 7.1 Hz). MS: 467 (M-1). Analysis calculated for C₂₁H₂₅FN₂O₇S: C, 53.84; H, 5.38; N, 5.98. Found: C, 54.00; H, 5.12; N, 5.87.

30

5

Example 43-[[4-(4-FLUOROPHENOXY)BENZENESULFONYL]-(1-HYDROXY-
CARBAMOYL-1-METHYLETHYL)AMINO]PROPIONIC ACID

The title compound was prepared from 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1-hydroxycarbamoyl-1-methylethyl)amino]propionic acid ethyl ester according to a procedure
10 analogous to that described in Example 2.


Mp: 162-162.5°C. MS: 439 (M-1). ¹H NMR (DMSO-d₆) δ 12.26 (s, 1 H) 10.10.38 (s, 1 H), 8.75 (s, 1 H), 7.86-7.88 (m, 2 H), 7.16-7.7.30 (m, 4 H), 7.03-7.06 (m, 2 H), 3.29-3.35 (m, 2 H), 2.47-2.59 (m, 2 H), 1.40 (s, 6 H).

5

CLAIMS

1.

A compound of the formula



I

or the pharmaceutically acceptable salts thereof, wherein

 R^1 is (C₁-C₆)alkyl;

10

 R^2 is (C₁-C₆)alkyl;or R^1 and R^2 taken together with the carbon atom to which they are attached form a ring selected from (C₅-C₇)cycloalkyl, 4-tetrahydropyranyl and 4-piperidinyl; R^3 is hydrogen or (C₁-C₆)alkyl; and

Y is a substituent on any of the carbon atoms of the phenyl ring capable of supporting an additional bond, independently selected from fluoro, chloro, trifluoromethyl, (C₁-C₆)alkoxy, trifluoromethoxy, difluoromethoxy and (C₁-C₆)alkyl.

2. A compound according to claim 1, wherein Y is hydrogen, fluoro or chloro.
3. A compound according to claim 1, wherein Y is 4-fluoro or 4-chloro.
4. A compound according to claim 1, wherein R^1 and R^2 taken together with the carbon atom to which they are attached form a cyclopentyl ring.
5. A compound according to claim 3, wherein R^1 and R^2 taken together with the carbon atom to which they are attached form a cyclopentyl ring.
6. A compound according to claim 1, wherein R^1 and R^2 taken together with the carbon atom to which they are attached form a 4-tetrahydropyranyl ring.
7. A compound according to claim 1, wherein R^1 and R^2 are both methyl.
8. A compound according to claim 3, wherein R^1 and R^2 are both methyl.
9. A compound according to claim 1, wherein R^3 is hydrogen.
10. A compound according to claim 3, wherein R^3 is hydrogen.
11. A compound according to claim 4, wherein R^3 is hydrogen.
12. A compound according to claim 1, wherein said compound is selected from the group consisting of:

5 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1-hydroxy-carbamoylcyclopentyl)amino]-
propionic acid ethyl ester,

 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1-hydroxy-carbamoylcyclopentyl)
amino]propionic acid,

 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1-hydroxycarbamoyl-1-
10 methylethyl)amino]propionic acid ethyl ester, and

 3-[[4-(4-fluorophenoxy)benzenesulfonyl]-(1-hydroxy-carbamoyl-1-
methylethyl)amino]propionic acid.

 13. A pharmaceutical composition for (a) the treatment of arthritis or cancer and
other diseases characterized by matrix metalloproteinase-13 activity or (b) the selective
15 inhibition of matrix metalloproteinase-13 in a mammal, including a human, comprising an amount
of a compound of claim 1 or a pharmaceutically acceptable salt thereof, effective in such
treatments or inhibition and a pharmaceutically acceptable carrier.

 14. A method for the selective inhibition of matrix metalloproteinases-13 in a
mammal, including a human, comprising administering to said mammal an effective amount of a
20 compound of claim 1 or a pharmaceutically acceptable salt thereof.

 15. A method for treating arthritis or cancer and other diseases characterized by
matrix metalloproteinase-13 activity in a mammal, including a human, comprising administering
to said mammal an amount of a compound of claim 1 or a pharmaceutically acceptable salt
thereof, effective in treating such a condition.

INTERNATIONAL SEARCH REPORT

Inter. Application No.

PCT/IB 98/01113

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07C311/29 C07D309/14 C07D211/66 A61K31/19 A61K31/215
A61K31/35 A61K31/445

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 606 046 A (CIBA-GEIGY AG) 13 July 1994 see claims	1-15
X	WO 96 27583 A (PFIZER) 12 September 1996 see claims	1-15



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

23 September 1998

Date of mailing of the international search report

14/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Van Geyt, J

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB 98/01113

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 14 and 15
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 14 and 15 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/IB 98/01113

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0606046 A	13-07-1994	US 5455258 A	03-10-1995
		AT 159012 T	15-10-1997
		AU 684255 B	11-12-1997
		AU 5265593 A	04-05-1995
		CA 2112779 A	07-07-1994
		DE 69314456 D	13-11-1997
		DE 69314456 T	26-02-1998
		DK 606046 T	04-05-1998
		ES 2107648 T	01-12-1997
		FI 940012 A	07-07-1994
		GR 3025611 T	31-03-1998
		HU 70536 A	30-10-1995
		JP 6256293 A	13-09-1994
		MX 9400276 A	29-07-1994
		NO 940038 A, B,	07-07-1994
		NZ 250517 A	26-10-1995
		SG 42933 A	17-10-1997
		US 5506242 A	09-04-1996
		US 5552419 A	03-09-1996
		US 5646167 A	08-07-1997
		US 5672615 A	30-09-1997
		ZA 9400048 A	11-08-1994
WO 9627583 A	12-09-1996	AU 5029396 A	23-09-1996
		BR 9607362 A	30-12-1997
		CA 2214720 A	12-09-1996
		CN 1181066 A	06-05-1998
		EP 0813520 A	29-12-1997
		FI 973613 A	05-11-1997
		HU 9800462 A	28-07-1998
		NO 974103 A	05-11-1997
		PL 322131 A	05-01-1998